Demonstrated in vivo, SYK interacts with and activates FLT3 directly, making FLT3-ITD more sensitive to SYK inhibition, further supporting the screening of FLT3-ITD as an important determinant of prognosis in AML patients [159]. This evidence concerns the gene FLT3 and acute myeloid leukemia.